Cardiovascular effects of sustained norepinephrine infusions in dogs. IV. Previous treatment with adrenergic blocking agents.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects; D006470:Hemorrhage / Q000139:chemically induced; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D009206:Myocardium / Q000473:pathology; D009638:Norepinephrine / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology*; D013997:Time Factors; D014655:Vascular Resistance / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D010643:Phenoxybenzamine; D011433:Propranolol; D009638:Norepinephrine